(Q33338785)

25 July 2017

1 reference

title

Heparin-induced thrombocytopenia: natural history, diagnosis, and management (English)

1 reference

heparin-induced thrombocytopenia

25 July 2017

1 reference

1 reference

Deitcher SR

1

1 reference

25 July 2017

Carman TL

series ordinal

2

1 reference

25 July 2017

publication date

1 January 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

6

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

113-119

1 reference

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin-associated thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

A 14-year study of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin-associated thrombocytopenia: a comparison of three heparin preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin induced thrombosis: an important complication of heparin prophylaxis for thromboembolic disease in surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin-induced thrombocytopenia and recurrent thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

The development of hirudin as an antithrombotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin-associated thrombocytopenia: Successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocyto

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1358836X0100600208

10.1177/1358836X0100600208

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference